Evidence map›Paper›PMID 39643727›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Radiopharmaceutical formulation and preliminary clinical dosimetry of [

Taraneh Sadat Zavvar, Anton Amadeus Hörmann, Mark Konijnenberg, Martin Kraihammer, Christian Mair, Ariane Kronthaler, Lieke Joosten, Peter Laverman, Leonhard Gruber, Gianpaolo di Santo and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Taraneh Sadat ZavvarDepartment of Nuclear Medicine, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Anton Amadeus HörmannDepartment of Nuclear Medicine, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Mark KonijnenbergDepartment of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD, Rotterdam, the Netherlands.
Martin KraihammerDepartment of Nuclear Medicine, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Christian MairDepartment of Nuclear Medicine, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Ariane KronthalerDepartment of Nuclear Medicine, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Lieke JoostenDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, 6525 GA, Nijmegen, the Netherlands.
Peter LavermanDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, 6525 GA, Nijmegen, the Netherlands.
Leonhard GruberDepartment of Radiology, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Gianpaolo di SantoDepartment of Nuclear Medicine, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Clemens DecristoforoDepartment of Nuclear Medicine, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Irene VirgoliniDepartment of Nuclear Medicine, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Elisabeth von GuggenbergDepartment of Nuclear Medicine, Medical University of Innsbruck, 6020, Innsbruck, Austria. elisabeth.von-guggenberg@i-med.ac.at.

Funding

Austrian Science Fund FWF DOC 110 doc.funds
6 · The paper itself

Abstract

purposeRadiolabelled minigastrin (MG) analogues targeting the cholecystokinin-2 receptor (CCK2R) have proven to be a promising approach for peptide receptor radionuclide therapy (PRRT). In this study, we report on the radiopharmaceutical development and standardization of the preparation of [

methodsFive individual batches of [

resultsThe automated cassette-based production of [

conclusionThe radiopharmaceutical development and the preclinical/clinical results support the initiation of a first clinical trial to evaluate the therapeutic potential of [

Indexed as

GastrinsLutetiumOrganometallic CompoundsRadioisotopesRadiopharmaceuticalsReceptors, PeptideAnimalsCell Line, TumorHumansMiceRadiochemistryRadiometryReceptor, Cholecystokinin BTissue DistributionGastrinsLutetiumLutetium-177minigastrinOrganometallic CompoundsRadioisotopesRadiopharmaceuticalsReceptor, Cholecystokinin BReceptors, PeptideCholecystokinin-2 receptorClinical translationLutetium-177MinigastrinPeptide receptor radionuclide therapyTheranostics

Identifiers

PMID39643727
PMCPMC11839890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.